{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Germ+Cell+Neoplasms&page=11", "query": { "condition": "Germ Cell Neoplasms", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 5241, "total_pages": 525, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Germ+Cell+Neoplasms&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Germ+Cell+Neoplasms&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-13T14:52:45.784Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03423628", "title": "A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Glioblastoma Multiforme", "Primary Glioblastoma Multiforme", "Brain Neoplasms, Malignant", "Leptomeningeal Disease (LMD)" ], "interventions": [ { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "AZD1390", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 159, "start_date": "2018-04-02", "completion_date": "2026-08-31", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-11-13T14:52:45.784Z", "location_count": 5, "location_summary": "Boston, Massachusetts • New York, New York • Pittsburgh, Pennsylvania + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03423628" }, { "nct_id": "NCT02419495", "title": "Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Fallopian Tube Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Renal Cell Carcinoma", "Ovarian Carcinoma", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Primary Peritoneal Carcinoma", "Stage III Lung Cancer AJCC v8", "Stage III Renal Cell Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Triple-Negative Breast Carcinoma", "Unresectable Lung Non-Small Cell Carcinoma", "Unresectable Melanoma", "Unresectable Renal Cell Carcinoma" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Eribulin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Selinexor", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 221, "start_date": "2015-06-26", "completion_date": "2024-09-16", "has_results": false, "last_update_posted_date": "2025-06-04", "last_synced_at": "2026-11-13T14:52:45.784Z", "location_count": 5, "location_summary": "Conroe, Texas • Houston, Texas • League City, Texas + 1 more", "locations": [ { "city": "Conroe", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "League City", "state": "Texas" }, { "city": "Sugar Land", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02419495" }, { "nct_id": "NCT07223034", "title": "A Study of 177Lu-PSMA-617 in People With Gliomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioma", "Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4)", "Glioblastoma, IDH-wildtype", "Diffuse Midline Glioma, H3 K27-Altered", "Diffuse Hemispheric Glioma, H3 G34-mutant", "Diffuse Pediatric-type High-grade Glioma, H3-wildtype and IDH-wildtype" ], "interventions": [ { "name": "Temozolomide", "type": "DRUG" }, { "name": "177Lu-PSMA-617", "type": "DRUG" }, { "name": "68Ga-PSMA-PET scan/ MRI", "type": "DIAGNOSTIC_TEST" }, { "name": "Quality of Life Questionnaires", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST", "BEHAVIORAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2025-10-27", "completion_date": "2027-10", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-11-13T14:52:45.784Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07223034" }, { "nct_id": "NCT00003234", "title": "Vinorelbine in Treating Children With Recurrent or Refractory Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors", "Neuroblastoma", "Sarcoma" ], "interventions": [ { "name": "vinorelbine tartrate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 50, "start_date": "1998-05", "completion_date": "2007-03", "has_results": false, "last_update_posted_date": "2014-07-28", "last_synced_at": "2026-11-13T14:52:45.784Z", "location_count": 200, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 149 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003234" }, { "nct_id": "NCT03870399", "title": "Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroendocrine Tumors", "Progesterone Receptor Positive Tumor", "Estrogen Receptor Positive Tumor" ], "interventions": [ { "name": "Tamoxifen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AC Camargo Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2019-03-13", "completion_date": "2023-05-13", "has_results": false, "last_update_posted_date": "2024-05-06", "last_synced_at": "2026-11-13T14:52:45.784Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03870399" }, { "nct_id": "NCT04216329", "title": "Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gliosarcoma", "Newly Diagnosed", "Glioblastoma" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Generic Radiation therapy (RT)", "type": "RADIATION" }, { "name": "Selective serotonin receptor (5-HT3) antagonists", "type": "OTHER" }, { "name": "Olanzapine", "type": "OTHER" }, { "name": "Salt tablets", "type": "DIETARY_SUPPLEMENT" }, { "name": "Anti-diarrheal", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "OTHER", "DIETARY_SUPPLEMENT" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2020-07-07", "completion_date": "2026-07-09", "has_results": true, "last_update_posted_date": "2026-10-27", "last_synced_at": "2026-11-13T14:52:45.784Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04216329" }, { "nct_id": "NCT00342537", "title": "Genetics of Familial Testicular Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Testicular Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "100 Years", "sex": "MALE", "summary": "4 Years to 100 Years · Male only" }, "enrollment_count": 1842, "start_date": "2004-01-02", "completion_date": "2020-07-14", "has_results": false, "last_update_posted_date": "2020-07-17", "last_synced_at": "2026-11-13T14:52:45.784Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00342537" }, { "nct_id": "NCT00003475", "title": "Antineoplaston Therapy in Treating Patients With Primary Malignant Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Brain Tumors" ], "interventions": [ { "name": "Antineoplaston therapy (Atengenal + Astugenal)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Burzynski Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 40, "start_date": "1996-02", "completion_date": "2011-05", "has_results": true, "last_update_posted_date": "2017-08-24", "last_synced_at": "2026-11-13T14:52:45.784Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003475" }, { "nct_id": "NCT04310397", "title": "Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8" ], "interventions": [ { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Spartalizumab", "type": "BIOLOGICAL" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2020-01-29", "completion_date": "2023-10-09", "has_results": true, "last_update_posted_date": "2024-10-30", "last_synced_at": "2026-11-13T14:52:45.784Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04310397" }, { "nct_id": "NCT04967196", "title": "Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Metastatic Melanoma", "Unresectable Melanoma" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Lymph Node Assessment", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2021-09-16", "completion_date": "2024-04-17", "has_results": false, "last_update_posted_date": "2024-12-10", "last_synced_at": "2026-11-13T14:52:45.784Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04967196" } ] }